Results 71 to 80 of about 756 (101)

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE

Journal of Allergy and Clinical Immunology: Global
Background: In the phase III SYNAPSE study, mepolizumab plus standard of care reduced total endoscopic nasal polyp score (NPS) versus that with placebo in patients with chronic rhinosinusitis with nasal polyps.
Amber U. Luong, MD, PhD, Joshua M. Levy, MD, MPH, MSc, Ludger Klimek, MD, PhD, Richard J. Harvey, MD, Jared Silver, MD, PhD, Steven G. Smith, PhD, Abby Fuller, MSc, Robert Chan, MD, Peter W. Hellings, MD, PhD   +8 more
doaj   +1 more source

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

Generative AI and Clinicians Show Comparable Prognostic Reasoning From Clinical Narratives in Biologic‐Treated CRSwNP

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 5, Page 645-654, October 2026.
ABSTRACT Objective To compare the ability of large language models (LLMs) and otolaryngologists to identify prognostic signals from brief clinical vignettes in CRSwNP. Methods In this blinded study, 68 adults initiating biologic therapy for CRSwNP (≥ 36 months follow‐up) were represented by standardized vignettes derived from documentation immediately ...
Sholem Hack, Chase Kahn, Ainhoa Garcia‐Lliberos, Cristina Rodriguez‐Prado, Ameen Biadsee, Maxime Fieux, Mark Liu, Eran Glikson, Masayoshi Takashima, Omar G. Ahmed, Raj Sindwani, Dennis M. Tang, Christopher R. Roxbury   +12 more
wiley   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Achieving Remission in Chronic Rhinosinusitis With Nasal Polyps Depends on Practical Utilization of Current Criteria and Does not Reflect Therapy Response: Results From a Multi‐National Cohort

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
Jan Hagemann, Tobias Albrecht, Sanna Toppila‐Salmi, Marie Lundberg, Annina Lyly, Katharina Geißler, Friederike Bärhold, Caroline Beutner, Inga Nierkamp, Mandy Cuevas, Nadine Gunder, Adam Chaker, Moritz Gröger, Ludger Klimek, Sven Becker   +14 more
wiley   +1 more source

Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma

Journal of Allergy and Clinical Immunology: Global
Background: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab’s impact on the clinical and health care resource utilization (HCRU) burden ...
Michelle L. Hernandez, MD, Tom Corbridge, MD, François Laliberté, MA, Malena Mahendran, MSc, Annalise Hilts, BA, Kaixin Zhang, MSc, Arijita Deb, PhD   +6 more
doaj   +1 more source

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Journal of Asthma and Allergy, 2020
Jared Silver,1 Michael Bogart,1 Elizabeth Packnett,2 Juan Wu,2 Donna McMorrow,2 Beth Hahn1 1US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Life Sciences, IBM Watson Health, Bethesda, MD, USACorrespondence: Beth Hahn Email beth.a.hahn@gsk ...
Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B   +5 more
doaj  

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan

Scientific Reports
Five-year survival in eosinophilic granulomatosis with polyangiitis (EGPA) exceeds 90%, but long-term prognosis is poor. We examined prognosis in 87 Japanese EGPA patients, seen between April 2018 and December 2024, after mepolizumab introduction ...
Yuga Yamashita, Nami Masumoto, Sachiko Takaoka, Takuya Nakashima, Kaho Matsunaga, Yuka Kodama, Kosuke Terada, Hinako Masumitsu, Atsushi Miyasaka, Tatsuya Muraoka, Takeshi Kaneko, Naomi Tsurikisawa   +11 more
doaj   +1 more source